bioAffinity https://validator.w3.org/feed/docs/rss2.html bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test Home New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedure Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic “Sputum as a Diagnostic Tool for the Treatment of Asthma” American Academy of Allergy, Asthma and Immunology (AAAAI) 2026 Annual Meeting March 1, 2026 Authors R. Titone, D.A. Porraz, D.W. Putnam, R.P. Jacob, W.E. Bauta and D.J. Elzi Publications bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients Sputum-Based Test May Identify Drug Targets in Asthma and COPD – Patient Care Online bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung Videos bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026 bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025 bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable Contact bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 CyPath® Lung in Practice: From Uncertainty to Clarity and Confidence bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025 bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung bioAffinity Technologies Reports Third Quarter 2025 Financial Results About Us bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds bioAffinity Technologies Reports Second Quarter 2025 Results bioAffinity Technologies Appoints New Members to Board of Directors New Test Shows Promise for Improving Lung Cancer Detection, Reducing Costs for VA – US Medicine, the Voice of Federal Medicine Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging and Low-Risk Serum Test Results bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules